Phase II, Multicenter, Prospective, Single Arm, Open Labeled Clinical Trial Investigating Pazopanib, a Multi-targeted Tyrosine Kinase Inhibitor (TKI) of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-Kit in Patients With Platinum-resistant Advanced Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 10 Aug 2016 Status changed from active, no longer recruiting to completed.
- 19 Mar 2012 Actual patient number is 28 according to ClinicalTrials.gov.